Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: 99mTc-cAbVCAM1-5 in atherosclerosis
NCT04483167Phase 1Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- Sep 2020
- Primary completion
- May 2023
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-cAbVCAM1-5 in atherosclerosis, sponsored by CHU Grenoble Alpes. Primary endpoints: Evaluation of 99mTc-cAbVCAM1-5 adverse events as assessed by all adverse event according to the NCI Common Terminology Criteria for Adverse Events (CTCAE)_v5.0 at 70 days, Evaluation of 99mTc-cAbVCAM1-5 adverse events as assessed by biological parameters at 6 hours and 2 more. Status: unknown.
02
Drugs
99mTc-cAbVCAM1-5
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT04483167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483167.